Polaris Group and The Ludwig Institute for Cancer Research (LICR) announced the initiation of enrollment for its Phase 2 clinical trial evaluating ADI-PEG 20 in the treatment of small cell lung cancer (SCLC). This study will evaluate the effectiveness of ADI-PEG 20 in patients with relapsed or refractory SCLC. Patients will be enrolled in two cohorts, each of which will have the sample size determined through a Simon two-stage design.
Arginine deiminase (ADI) is a microbial enzyme that degrades the amino acid arginine. ADI-PEG 20 is ADI conjugated with polyethylene glycol. Since arginine can be internally synthesized in normal cells via the urea cycle but not in certain cancer cells if they lack the necessary enzymes to make arginine, deprivation of arginine caused by ADI-PEG 20 can selectively kill cancer cells without affecting the growth of normal cells.
For more information call (858) 452-6688 or visit www.polarispharma.com.